WO2007098951A2 - Method and apparatus for extraction of protein material from silkworm glands - Google Patents
Method and apparatus for extraction of protein material from silkworm glands Download PDFInfo
- Publication number
- WO2007098951A2 WO2007098951A2 PCT/EP2007/001775 EP2007001775W WO2007098951A2 WO 2007098951 A2 WO2007098951 A2 WO 2007098951A2 EP 2007001775 W EP2007001775 W EP 2007001775W WO 2007098951 A2 WO2007098951 A2 WO 2007098951A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gland
- glands
- silkworm
- buffer solution
- arthropod
- Prior art date
Links
- 210000004907 gland Anatomy 0.000 title claims abstract description 152
- 239000000463 material Substances 0.000 title claims abstract description 80
- 238000000034 method Methods 0.000 title claims abstract description 36
- 238000000605 extraction Methods 0.000 title claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 title claims description 58
- 108090000623 proteins and genes Proteins 0.000 title claims description 58
- 241000255789 Bombyx mori Species 0.000 title description 62
- 241000238421 Arthropoda Species 0.000 claims abstract description 29
- 239000007853 buffer solution Substances 0.000 claims abstract description 26
- 239000000654 additive Substances 0.000 claims description 40
- 108010022355 Fibroins Proteins 0.000 claims description 19
- 230000000996 additive effect Effects 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 241000255783 Bombycidae Species 0.000 claims description 2
- 241000894007 species Species 0.000 claims 1
- 239000013049 sediment Substances 0.000 abstract description 2
- 210000000981 epithelium Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000872 buffer Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- -1 Fe2O3 Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 238000009987 spinning Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000012670 alkaline solution Substances 0.000 description 3
- 230000003592 biomimetic effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000012846 protein folding Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004150 EU approved colour Substances 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000033558 biomineral tissue development Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000030788 protein refolding Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000242757 Anthozoa Species 0.000 description 1
- 108010000241 Arthropod Proteins Proteins 0.000 description 1
- 241000909872 Attacus Species 0.000 description 1
- 241000255791 Bombyx Species 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical class C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000256008 Samia Species 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 108010013296 Sericins Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000679046 Teleas Species 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- CGMRCMMOCQYHAD-UHFFFAOYSA-J dicalcium hydroxide phosphate Chemical compound [OH-].[Ca++].[Ca++].[O-]P([O-])([O-])=O CGMRCMMOCQYHAD-UHFFFAOYSA-J 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229910052587 fluorapatite Inorganic materials 0.000 description 1
- 229940077441 fluorapatite Drugs 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- ZJZXSOKJEJFHCP-UHFFFAOYSA-M lithium;thiocyanate Chemical compound [Li+].[S-]C#N ZJZXSOKJEJFHCP-UHFFFAOYSA-M 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006259 organic additive Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 229910001848 post-transition metal Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 229910001845 yogo sapphire Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/06—Hydrolysis; Cell lysis; Extraction of intracellular or cell wall material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43586—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from silkworms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
- C12M3/06—Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
- C12M3/062—Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means with flat plate filter elements
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
- C12M3/08—Apparatus for tissue disaggregation
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01B—MECHANICAL TREATMENT OF NATURAL FIBROUS OR FILAMENTARY MATERIAL TO OBTAIN FIBRES OF FILAMENTS, e.g. FOR SPINNING
- D01B7/00—Obtaining silk fibres or filaments
Definitions
- the Application relates to an apparatus and method for the extraction of material from wild- type or recombinant arthropod glands.
- EU 2.3 MDa elementary unit
- solutions of silk proteins are made as regenerated silk solutions out of cocoons or silk threads which are dissolved in solubilisation agents (e.g. lithium bromide) and refolded through dialysis or other buffer exchange techniques (see, for example, Altmann et al., Biomaterials 2003, 24, 401-416).
- solubilisation agents e.g. lithium bromide
- dialysis or other buffer exchange techniques see, for example, Altmann et al., Biomaterials 2003, 24, 401-416.
- the differences between the native silk proteins as produced and stored in the glands of arthropods, such as silkworms, (i.e. in their high molecular weigh EU conformation) and the regenerated silk proteins (disclosed above) are such that the regenerated silk proteins produced by current techniques have at most "native-like" features, i.e. the regenerated silk proteins have some properties in common but cannot be said to be identical or substantially identical with the native silk proteins.
- the native silk proteins are defined as those proteins found in their native protein conformation, i.e. with the primary, secondary, tertiary and quaternary folding structures similar or essentially similar to the wild type protein (Thomas E.
- European Patent Application No 1241178 (assigned to the National Institute of Agrobiological Sciences and Kowa Co) teaches a method for the production of silk fibroin by dissolving cocoons in an aqueous alkaline solution or an aqueous urea solution.
- the aqueous alkaline solution described in the examples of the '178 patent application is sodium carbonate or lithium thiocyanate at a pH of 7. Subsequently acetone or alcohol is added to the aqueous alkaline solution to precipitate the fibroin.
- the results shown in the patent application do not indicate that high molecular weight silk proteins exhibiting native tertiary and quaternary protein folding conformations were produced.
- the '178 patent application reports (paragraph 18) also a method in which the silk gland is extracted from the body of a silkworm followed by extraction of the protein from a silk gland lumen.
- the disclosure suggests, however, that the process is not suitable for industrial production because the fibroin obtained contains impurities such as silkworm humor and silkworm gland cells.
- a method for the extraction of native silk proteins from silkworm glands has been described in US Patent No 7,041,797 (Vollrath, assigned to Spintec Engineering GmbH).
- the '797 patent describes an approach in which the silk glands are removed from the body of the silkworm followed by removal of an epithelial layer of the silk glands. The method works well for the manual extraction from individual ones of the silk glands.
- Japanese Patent Application JP-A-2268693 (Asahi) teaches a method of cultivating a silk gland obtained from silkworms (such as from Bombyx mori) and using a culture medium. The culture medium is removed using dialysis to obtain an aqueous solution of the silk fibroin.
- the inventors in the '693 patent application did not consider how to incorporate additives homogenously into the highly viscous content of the silk gland.
- a cruder method for obtaining fibroin protein is disclosed in Japanese Patent Application JP- A-3209399 (Terumo) in which the heads are cut off of grown silkworms.
- the fibroin protein is then harvested by pressing the abdomen of the silkworm to extract the fibroin protein.
- Sericin is removed from the resulting protein mixture by treating the protein mixture with a weak alkali, such as Na 2 CO 3.
- the inventors of the '399 patent application did not teach how to include additives in the protein mixtures.
- the method of the '399 patent application has the disadvantage that incorporation of impurities from the silkworm body is not easily avoided. These impurities have to be removed or they may affect the properties of biomimetically spun fibres spun or of coated or moulded objects produced with said protein mixtures.
- an apparatus for the extraction of material from a gland of an arthropod comprising a holding device by which at least part of the gland is held.
- a buffer solution at least partially (but not necessarily completely) immerses the gland. The material is released from the gland into the buffer solution.
- the material is ultimately sedimented in a collection area at the bottom of the apparatus.
- the apparatus ensures that material from two or more silkworm glands from one or more arthropods (such as silkworms) is substantially homogenously mixed together in the apparatus. At least partially immersing the silkworm gland in the buffer solution means that osmotic pressure, enzymatic or mechanical dissection ensures that the material is released from the silkworm gland into the buffer solution.
- the apparatus further incorporates a porous support, such as a porous net or a porous plate, which is placed between the holding device and the collection area of the material.
- a porous support such as a porous net or a porous plate, which is placed between the holding device and the collection area of the material.
- the porous support provides an efficient technical solution for breaking up the highly viscous protein content flowing out of the glands, resulting in a uniformly mixed material collected in the collection area.
- the porous support also serves as a technical means to control and change material properties of the collected material (i.e. the contents of the gland). For example, by changing the mesh or pore size and/or adjusting the position of the porous support relative to the position of the gland on the holding device and/or relative to the position of the collection area of the apparatus, it is possible to control exposure of the material to the buffer solution (and any additives in the buffer solution) in the apparatus.
- the exposure of the material to the buffer solution can also be controlled by using a non-porous support whereby the position of the non-porous support is such that the material is guided towards the collection area of the apparatus.
- Additives can be incorporated into the buffer solution. It has been found that the solubilisation and sedimentation of the material in the buffer solution leads to a substantially even distribution of additives within the material.
- a method comprising: Providing a gland containing at least partially the material; making an opening in the gland and positioning the gland by a holding device such that the gland is at least partially immersed in a buffer solution such that the material can exit the gland.
- porous support such as a porous plate or a porous net.
- a porous support breaks up the highly viscous protein content flowing out of the glands which results in a uniformly mixed material collected in the collection area. Finally the material is collected at the bottom of the apparatus.
- the material consists of native or recombinant biomaterials which can be produced in arthropod glands such as for example proteins, peptides or carbohydrates or other suitable biological molecules and/or a combination of these.
- the materials can be used for a number of purposes including, but not limited to, the manufacture of fibres or films.
- the material is native or recombinant fibroin or fibroinfusion proteins known to one skilled in the art of recombinant silkworm technologies.
- Extraction of arthropod protein in accordance with the invention avoids the need to use protein refolding techniques as is necessary if silk proteins are made from regenerated silk solution. Instead, the apparatus and method presented here enables a large scale extraction of native materials made and stored by the arthropod in the glands. By avoiding the protein refolding techniques and by using mild protein purification conditions, all or most of the functionality conferred by natural synthesis of the biomaterial in the arthropod's glands can be retained.
- the disclosed invention allows an efficient harvesting of native fibroin or recombinant fibroin without destroying high molecular weight multimeric fibroin protein complexes (tertiary and quaternary folding, described for example in Inoue et al in Eur. J. Biochem. 2004, 271, 356-366) by avoiding the use of denaturing agents which are widely used for making regenerated silks (for example see Altmann et al., Biomaterials 2003, 24, 401-416).
- the disclosed apparatus enables a benign harvesting technique and preservation of the native features of fibroin in the extracted silkworm gland content.
- the apparatus forms the basis for the production of novel films, coatings, moulded objects or spun silk materials based on the enhanced properties of native compared with regenerated silk proteins.
- the invention enables the mixing of the arthropod gland content with buffer and/or additives, thereby providing a means for the production of novel silks with properties conferred by the permanent or transient integration of additives.
- the solution is an aqueous solution and does not require any organic solvents as refolding agents for silk proteins (unlike the prior art discussed above), it is believed that, for example, any labile protein or peptide can be used as additives.
- Other examples of potential additives are listed below.
- the invention also enables the homogenisation of the extracted gland content by passage through a porous net, thereby providing for homogenous mixing of the gland contents from more than one arthropod.
- the disclosed apparatus enables the operator to manufacture gland content solutions with tuneable material properties such as for example protein concentration or biochemical composition by controlling parameters such as buffer composition, dimensions of openings in a porous support, flow distance of materials inside the apparatus and size of the collection area.
- Fig. 1 shows the apparatus with a porous support according to the current invention.
- Fig. 2 shows the use of the apparatus for harvesting arthropod gland contents.
- Fig. 3 shows the method of use of the apparatus.
- Fig. 4 shows the stress strain curve of Example 4.
- Fig. 5 shows the apparatus with a solid support according to the current invention. Detailed Description of the Invention
- Figs. 1 and 5 show an apparatus 5 used in the invention.
- the apparatus 5 comprises a container 10, a material collection area 20, and a buffer solution 30 with one or more additives 40.
- the one or more additives 40 may be added at any stage during the use of the apparatus or alternatively no additives 40 need to be added.
- the apparatus 5 further contains a height adjustable (indicated by the arrow) gland holding device 50 which holds one or more arthropod glands removed from arthropods in position to facilitate release (elution) of contents of the one or more glands.
- the apparatus 5 contains a height and position adjustable (indicated by the arrows) support 60 with a pore size of 0.1 - 10 mm.
- the support 60 can be a porous net or a porous plate as indicated in Fig.1 or a solid plate as indicated by Fig.5.
- the buffer solution 30 may contain for example 100 mM Tris or any other buffer type known to one skilled in the art of protein purification.
- the additives 40 may be by way of example only a therapeutically active substances or colouring agents.
- Fig. 2 shows the placement of the arthropod glands 70 on the holding device 50 (indicated by the arrow).
- the holding device 50 is automatically loaded with the arthropod glands 70 by one or several robotic gland pick-up and transfer devices 80.
- the apparatus 5 can also be loaded manually.
- the gland content 90 is released out of the arthropod gland 70 and is collected in the material collection area 20.
- the porous support 60 may be used to improve homogeneous mixing with and increase exposure of the gland content 90 to the buffer 30 with or without the additives 40.
- no porous support 60 may be used at all thereby preserving the concentration of eluted gland content 90 as much as possible.
- Fig. 3 summarises the method of use for apparatus 10.
- a first step 200 the container 10 is filled with the buffer 30 with or without the one or more additives 40.
- the glands 70 are extracted from bodies of the arthropods, such as silkworms. This can be done, for example, using a method described in US Patent No. 7,041,797. At least one opening is made into an epithelial cell wall of the silkworm glands so that the content (silk proteins) can be released from the inside of the silkworm glands.
- the opening in the epithelial cell wall can be made by ultrasound, mechanical cutting or enzymatic dissection.
- the opening in the epithelial cell wall can also be carried out by cutting the silkworm gland roughly in half. The exact position of the opening in the epithelial cell wall and method of making the opening are not crucial for practicing the invention.
- the opened glands 70 are then placed either manually or with one of the robotic pick-up and transfer devices 80 onto the holding device 50 of the apparatus 10.
- pick-and-place devices are known to one skilled in the art of laboratory automation and allow the physical manipulation of the silkworm gland 70 by means of a pick-and-place functional device, such as a gripper.
- the transferred silkworm glands 70 are arranged on the holding device 50 in a manner enabling the efficient release of the content 90 of the silkworm gland 70 and an efficient packing of the silkworm glands 70 inside the container 10.
- the silkworm glands 70 from about 7 silkworms are used, however this is not limiting of the invention and can be easily scaled up to several magnitudes by increasing the dimensions of the holding device 50 and of the apparatus 5.
- gland content 90 flows out of the silkworm gland 70 into the container 10 and is collected in the material collection area 20.
- the gland content 90 passes through porous support 60.
- the use of the porous support 60 has the advantage of improving homogeneity and adjusting material properties of the gland content 90 by varying the positions of the porous support 60 and/or the holding device 50 in the container 10.
- the porous support 60 may also be used for reducing impurities from the released gland content 90.
- the gland content 90 collected in the material collection area 20 may be stored in the container 10 or transferred into a further suitable storage containers (not shown).
- the collected gland content 90 has a protein content of around 1-30% and can be loaded with useful additives during or after the extraction process to confer novel functionality to the collected gland material.
- the collected gland content 90 is substantially homogeneous, especially if the collected gland content 90 was passed through the porous support 60. This homogeneous distribution of the collected gland content 90 and the ability to confer the one or more additives to the gland contents 90 contrasts with prior art methods in which it has not been possible to mix the material native silk proteins from more than one silkworm gland 70 or to incorporate the one or more additives 40 into the material..
- this method is equally applicable to native proteins and peptides (not only limited to silk proteins) and their recombinant analogous and fusion proteins extracted in native form from the glands of wild type or recombinant arthropods such as silkworms from the family Bombycidae, including but not limited to silkworms from the genera Antherea, Attacus, Samia, Bombyx and Telea.
- the extracted materials include, but are not limited to, ABAB-block polymer type peptides and proteins, such as fibroin.
- the one or more additives 40 can be added to the extracted gland content 90, either to the buffer solution 30 at any stage of the extraction or directly to gland content 90 harvested in the material collection area 20.
- Organic additives o Small molecular entities o ' Peptides o Proteins o Carbohydrates o Lipids o Nucleic acids such as DNA, RNA, PNAs and other nucleic acid analogues with more than 100 bases length as well as fragments thereof with less than 100 bases length such as for example siRNAs
- Inorganic additives o Additives or precursors that improve or render mechanical, optical, electrical or catalytic properties o Minerals such as phosphates, carbonates, sulphates, fluorides, silicates etc. and mineraloids such as clays, talc, and silicas, o Salts of alkali and alkaline earth metals, transition metals, post transition metals and alloys thereof, o Metal complexes such as metal ions coordinated with EDTA or other chelating agents, o Insulators such as metal oxides like Fe 2 O 3 , Al 2 O 3 , TiO 2 , o Any IH-V or II- VI semiconductor and conductors, such as metals and alloys thereof, o Carbon-based additives, such as fullerenes, carbon nanotubes, fibres or rods, graphite
- Hydrophobic, hydrophilic or amphiphilic additives to adjust the solubility of the gland content in the buffer solution and thus provide differing concentrations of extracted material.
- Physiologically active compounds such as o Antibodies and their analogous o Antiseptics, antiviral agents and antibiotics o Anti-coagulants and anti-thrombotics o Vasodilatory agents o Chemotherapeutic agents o Antiproliferative agents o Anti-rejection or immunosuppressive agents o Agents acting on the central and peripheral nervous system o Analgesics o Anti-inflammatory agents o Hormones such as steroids o Mineralization agents for tooth regeneration such as fluorapatite for tooth regeneration o Mineralization agents for bone regeneration such as hydroxylapatite, tricalcium phosphate, marine animal derived particles such as corals and chitosans and the like o Growth factors such as • bone morphogenic proteins BMPs • bone morphogenic-like proteins GFD 's
- TGFs transforming growth factors
- VEGFs vascular endothelial growth factors
- platelet-derived growth factors PDGFs o Proteins functioning as cell or protein binding agents such as collagen IV, polylysine, fibronectin, cadherins, ICAM, V-CAM, N-CAM, selectins, neurofascins, oxonin, neuroglinin, fascilin o Cell-binding motives such as for example the RGD or RADAR recognition sites for cell adhesion molecules o Wound healing agents o Agents for preventing scar-formation such as for example Cordaneurin o Other naturally derived or genetically engineered therapeutically active proteins, polysaccharides, glycoproteins or lipoproteins o Therapeutically active cells such as for example stem cells or autologous cells derived from a site of the patient • Agents for detecting changes of pH such as neutral red
- Agents such as biodegradable polymers which degrade at controllable rates thereby enabling controlled biodegradability
- Agents such as protease inhibitors which inhibit protease activity for example in the site of implantation in the patient thereby enabling controlled biodegradability
- Aprotic solvents improving hydrogen bond formation in silk proteins such as ether, ester, acidanhydride, ketones (e.g. acetone), tertiary amines, dimethylformamide, pyridine, furane, thiophen, trichlorethane, chloroform and other halogenated hydrocarbons, dimethylsulphoxide, dimethylsulphate, dimethylcarbonate, imsol, anisol, nitromethane.
- ketones e.g. acetone
- tertiary amines dimethylformamide
- pyridine furane
- furane thiophen
- trichlorethane trichlorethane
- chloroform and other halogenated hydrocarbons dimethylsulphoxide, dimethylsulphate, dimethylcarbonate, imsol, anisol, nitromethane.
- Naturally derived or genetically engineered colouring agents such as green fluorescent protein
- Naturally derived or genetically engineered structural load bearing proteins such as actin, silk, collagen or fibronectin and analogous or derivates thereof
- Water soluble polymers such as polylactic acid or polycaprolactone
- the extracted gland material 90 can be used for forming objects, for example by coating, moulding or spinning as defined in the spinning apparatus disclosed in European Patent 1244828. If the one or more additives 40 are added to the extracted gland material 90, the formed objects can have additional properties. For example, one of the additives 40 to encourage the growth of tissue could be added to the extracted gland material 90 so that the formed objects can be used as a medical implant.
- the silkworm glands of four Bombyx mori silkworms at the end of their fifth instar were extracted by removing the silkworm gland from the body of the Bombyx mori silkworms as described above with reference to the US Patent No. 7,041,797. Each of the silkworm glands was cut into half. The posterior halves of the silkworm glands were placed with a pair of forceps on a net positioned inside a Petri dish which was filled with 100 mM ammonium acetate buffer having a pH 7.8. In total, eight posterior silkworm glands 70 were transferred. The eight silkworm glands 70 were incubated for 60 min for osmotic shock and release of the content of the silkworm gland 70.
- the emptied silkworm glands 70 were then removed from the surface of the net using a pair of forceps. Where necessary, a sliding movement over the edge of the Petri dish was used in order to extract any remaining silkworm gland material left inside the silkworm gland. The extracted silkworm gland material was left overnight on the surface of the net which allowed the silkworm gland material to pass through the net and sediment at the bottom of the Petri dish. The net was then removed from the Petri dish and the silkworm protein from the silkworm gland harvested using a 5 ml disposable syringe.
- additives 40 ("dopants") in the gland content during the extraction
- eight posterior halves of the silkworm glands were extracted in a buffer solution of 100 mM ammonium acetate buffer and 1.75 mM neutral red.
- the buffer solution had a pH 7.8. This was compared with four posterior halves extracted in 100 mM ammonium acetate buffer solution at pH 7.8 without further additives.
- the addition of the additive 40 to the buffer solution did not lead to aggregation or destabilisation of the extracted gland material from the silkworm gland.
- the gland material containing the neutral red additive was transferred into a Petri dish and dried at 50°C to form a film.
- the film was found to be stable and retained red colour when incubated in water at room temperature for three months, thus demonstrating the stable integration of the additive into the gland material.
- the silkworm gland material was extracted as described above containing 0,18 mM neutral red additive was further tested successfully for spinnability using the biomimetic spinning device of European Patent 1244828 yielding uniformly red coloured silk fibres with diameter of about 5 ⁇ m collected on two aluminium reels.
- Example 4 Material properties of extracted gland materials A film was cast using the gland material extracted in accordance with the method of Example 1. The cast film was water insoluble and did not change its properties upon repeated wetting and drying in water or organic solvents. Tensile testing was performed in dH2O on a ZwickRoell TC-FR2.5TN tensile tester at lOmm/min with sample geometries of 40mm x 2,5mm x 0,06mm. The film exhibited breaking strength in dH2O of about 20 MPa at approximately 100% breaking elongation (for data see figure 4).
- the silkworm glands of seven Bombyx mori silkworms at the end of their fifth instar were extracted by removing the silkworm gland from the body of the silkworms as described for example in the US patent application number 7,041,797. Each of the silkworm glands was cut into half.
- the posterior halves of the silkworm glands (in total 14) were placed with a pair of forceps on a bar positioned at the top of a cylinder with approx. 30 mm diameter and approx. 100 mm length containing a 10OmM ammonium acetate, pH 7.8 buffer and a net with mesh size 1 mm, positioned at approx. 46 mm distance from the closed bottom of the cylinder.
- the whole content of the opened silk glands was released, passed through the net and collected at the bottom of the device.
- the protein concentration of the collected whole gland content was then determined by drying in an oven at 60 0 C.
- the extraction procedure was performed five times, yielding gland protein concentrations of 7.0%, 7.2%, 7.2%, 6.7% and 7.1% and an overall protein concentration of 7 ⁇ 0.22%
- Example 5 For each one of the silk gland extractions, 14 posterior halves were prepared as described in Example 5. The concentration of the extracted gland content was adjusted by varying the position of the porous net to the bottom of the cylinder between 10 mm, 20 mm and 46 mm. One of the extractions was performed with the porous net removed allowing direct passage of the gland content from the gland to the bottom of the cylinder. The protein concentration of the collected whole gland content was then determined by drying in an oven at 60°C. The resulting protein concentrations were: 20% for extraction without the porous net, 15% with the net positioned at 10 mm distance from the bottom of the cylinder, 11% with 20 mm distance, 7% with 46 mm distance and 5% with 100 mm distance.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Sustainable Development (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Insects & Arthropods (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Textile Engineering (AREA)
- Mechanical Engineering (AREA)
- Water Supply & Treatment (AREA)
- Peptides Or Proteins (AREA)
- Catching Or Destruction (AREA)
- Medicines Containing Plant Substances (AREA)
- Extraction Or Liquid Replacement (AREA)
Abstract
An apparatus and method for the extraction of material from glands of arthropods. The apparatus (5) comprises a container (10) in which at least part of the glands are placed and a buffer solution (30) at least partially immersing the glands. Gland material is collected in the material collection area (20) of container (10). In use the material is released from glands into the buffer solution (30) and sedimented at the bottom of the container (10). The method comprises: a first step of removing from a body of the arthropod the gland containing at least partially the material; a second step of making an opening in an epithelium of the gland; and a third step of placing the gland in a container (10) at least partially immersed in a buffer solution (30) such that the materials exit the glands and sediments in the material collection area (20) of container (10).
Description
Description
Field of the Invention
The Application relates to an apparatus and method for the extraction of material from wild- type or recombinant arthropod glands.
Prior Art
Inoue et al in Eur. J. Biochem. 2004, 271, 356-366, described the secretion of native silk fibroin of Bombyx mori from the posterior silk gland as a 2.3 MDa elementary unit (hereinafter termed EU) which consists of six sets of a disulfide-linked heavy chain-light chain fibroin heterodimer and one molecule of P25.
Currently, solutions of silk proteins (such as fibroin and other proteins) are made as regenerated silk solutions out of cocoons or silk threads which are dissolved in solubilisation agents (e.g. lithium bromide) and refolded through dialysis or other buffer exchange techniques (see, for example, Altmann et al., Biomaterials 2003, 24, 401-416). Given the known challenges in producing active proteins through refolding after solubilisation in protein folding/chaotropic agents (Vallejo and Rinas, Microbial Cell Factories, 2004, doi:10.1186/1475-2859-3-11), a person skilled in the art will appreciate the technical hurdles which have to be solved in order to produce correctly folded, native fibroin EUs from regenerated silk solutions. It is therefore not surprising that there has been no report to date on the successful production of high molecular weight fibroin assembled in EU conformation out of regenerated silk solutions.
The differences between the native silk proteins as produced and stored in the glands of arthropods, such as silkworms, (i.e. in their high molecular weigh EU conformation) and the regenerated silk proteins (disclosed above) are such that the regenerated silk proteins produced by current techniques have at most "native-like" features, i.e. the regenerated silk
proteins have some properties in common but cannot be said to be identical or substantially identical with the native silk proteins. The native silk proteins are defined as those proteins found in their native protein conformation, i.e. with the primary, secondary, tertiary and quaternary folding structures similar or essentially similar to the wild type protein (Thomas E. Creighton, Proteins, Second Edition, 1993, 232-236, ISBN 0-7167-2317-4). The differences of regenerated silk proteins in their protein folding pattern, especially for their tertiary and quaternary folding compared to native silk proteins have apparently no negative impact on their use as cosmetic or pharmaceutical ingredients (as described, for example, by Tsubouchi et al. in international patent application PCT/JPOl/02250). However, for more demanding applications, such as the production of mechanically strong films, coatings and moulded objects or the biomimetic spinning of silks (as described by Vollrath and Knight in European Patent 1244828, assigned to Spintec Engineering GmbH), the correct folding and self- assembly of the silk proteins used for production of said materials plays a role in determining the mechanical strength and functional features of the formed materials. Due to the differences between the regenerated silk proteins and the native silk proteins noted above, the quality of regenerated silks has not been sufficient for the production of high quality silk materials through moulding, coating or biomimetic spinning as described in the above mentioned European patent 1244828.
European Patent Application No 1241178 (assigned to the National Institute of Agrobiological Sciences and Kowa Co) teaches a method for the production of silk fibroin by dissolving cocoons in an aqueous alkaline solution or an aqueous urea solution. The aqueous alkaline solution described in the examples of the '178 patent application is sodium carbonate or lithium thiocyanate at a pH of 7. Subsequently acetone or alcohol is added to the aqueous alkaline solution to precipitate the fibroin. The results shown in the patent application do not indicate that high molecular weight silk proteins exhibiting native tertiary and quaternary protein folding conformations were produced.
The '178 patent application reports (paragraph 18) also a method in which the silk gland is extracted from the body of a silkworm followed by extraction of the protein from a silk gland lumen. The disclosure suggests, however, that the process is not suitable for industrial production because the fibroin obtained contains impurities such as silkworm humor and silkworm gland cells.
A method for the extraction of native silk proteins from silkworm glands has been described in US Patent No 7,041,797 (Vollrath, assigned to Spintec Engineering GmbH). The '797 patent describes an approach in which the silk glands are removed from the body of the silkworm followed by removal of an epithelial layer of the silk glands. The method works well for the manual extraction from individual ones of the silk glands. However, it is tedious and time consuming if a larger number of the silk glands need to be extracted. It is thus impracticable as a production method for the native proteins from the silk glands on an industrial scale. The inventor of the '797 patent has also not detailed a method or an apparatus which allows for the efficient and homogeneous mixing and pooling of proteins extracted from the silk glands as well as for the incorporation of additives in the extracted content from the silk gland.
Similarly Japanese Patent Application JP-A-2268693 (Asahi) teaches a method of cultivating a silk gland obtained from silkworms (such as from Bombyx mori) and using a culture medium. The culture medium is removed using dialysis to obtain an aqueous solution of the silk fibroin. However, the inventors in the '693 patent application did not consider how to incorporate additives homogenously into the highly viscous content of the silk gland.
A cruder method for obtaining fibroin protein is disclosed in Japanese Patent Application JP- A-3209399 (Terumo) in which the heads are cut off of grown silkworms. The fibroin protein is then harvested by pressing the abdomen of the silkworm to extract the fibroin protein. Sericin is removed from the resulting protein mixture by treating the protein mixture with a weak alkali, such as Na2CO3. The inventors of the '399 patent application did not teach how to include additives in the protein mixtures. Further the method of the '399 patent application has the disadvantage that incorporation of impurities from the silkworm body is not easily avoided. These impurities have to be removed or they may affect the properties of biomimetically spun fibres spun or of coated or moulded objects produced with said protein mixtures.
Summary of the Invention
There is therefore a need for a method and apparatus to efficiently extract native proteins from arthropod glands.
There is furthermore a need to incorporate additives into said arthropod gland proteins.
There is furthermore a need to homogenously mix arthropod gland proteins extracted from more than one arthropod.
These and other objects are solved by an apparatus for the extraction of material from a gland of an arthropod (such as a silkworm) comprising a holding device by which at least part of the gland is held. A buffer solution at least partially (but not necessarily completely) immerses the gland. The material is released from the gland into the buffer solution.
The material is ultimately sedimented in a collection area at the bottom of the apparatus.
The apparatus ensures that material from two or more silkworm glands from one or more arthropods (such as silkworms) is substantially homogenously mixed together in the apparatus. At least partially immersing the silkworm gland in the buffer solution means that osmotic pressure, enzymatic or mechanical dissection ensures that the material is released from the silkworm gland into the buffer solution.
The apparatus further incorporates a porous support, such as a porous net or a porous plate, which is placed between the holding device and the collection area of the material. The porous support provides an efficient technical solution for breaking up the highly viscous protein content flowing out of the glands, resulting in a uniformly mixed material collected in the collection area.
The porous support also serves as a technical means to control and change material properties of the collected material (i.e. the contents of the gland). For example, by changing the mesh or pore size and/or adjusting the position of the porous support relative to the position of the gland on the holding device and/or relative to the position of the collection area of the apparatus, it is possible to control exposure of the material to the buffer solution (and any additives in the buffer solution) in the apparatus. In a further embodiment, the exposure of the material to the buffer solution can also be controlled by using a non-porous support whereby the position of the non-porous support is such that the material is guided towards the collection area of the apparatus.
Additives can be incorporated into the buffer solution. It has been found that the solubilisation and sedimentation of the material in the buffer solution leads to a substantially even distribution of additives within the material.
These and other objects are also solved by a method comprising: Providing a gland containing at least partially the material; making an opening in the gland and positioning the gland by a holding device such that the gland is at least partially immersed in a buffer solution such that the material can exit the gland.
It is also possible to pass the material through a porous support (such as a porous plate or a porous net). As discussed above the provision of the porous support breaks up the highly viscous protein content flowing out of the glands which results in a uniformly mixed material collected in the collection area. Finally the material is collected at the bottom of the apparatus.
As is discussed below, the material consists of native or recombinant biomaterials which can be produced in arthropod glands such as for example proteins, peptides or carbohydrates or other suitable biological molecules and/or a combination of these. The materials can be used for a number of purposes including, but not limited to, the manufacture of fibres or films. Preferably the material is native or recombinant fibroin or fibroinfusion proteins known to one skilled in the art of recombinant silkworm technologies.
Extraction of arthropod protein in accordance with the invention avoids the need to use protein refolding techniques as is necessary if silk proteins are made from regenerated silk solution. Instead, the apparatus and method presented here enables a large scale extraction of native materials made and stored by the arthropod in the glands. By avoiding the protein refolding techniques and by using mild protein purification conditions, all or most of the functionality conferred by natural synthesis of the biomaterial in the arthropod's glands can be retained. For example, in the case of the silkworm the disclosed invention allows an efficient harvesting of native fibroin or recombinant fibroin without destroying high molecular weight multimeric fibroin protein complexes (tertiary and quaternary folding, described for example in Inoue et al in Eur. J. Biochem. 2004, 271, 356-366) by avoiding the use of denaturing agents which are widely used for making regenerated silks (for example see
Altmann et al., Biomaterials 2003, 24, 401-416). From a commercial point of view, the disclosed apparatus enables a benign harvesting technique and preservation of the native features of fibroin in the extracted silkworm gland content. In addition, the apparatus forms the basis for the production of novel films, coatings, moulded objects or spun silk materials based on the enhanced properties of native compared with regenerated silk proteins.
Furthermore, the invention enables the mixing of the arthropod gland content with buffer and/or additives, thereby providing a means for the production of novel silks with properties conferred by the permanent or transient integration of additives. Since the solution is an aqueous solution and does not require any organic solvents as refolding agents for silk proteins (unlike the prior art discussed above), it is believed that, for example, any labile protein or peptide can be used as additives. Other examples of potential additives are listed below.
The invention also enables the homogenisation of the extracted gland content by passage through a porous net, thereby providing for homogenous mixing of the gland contents from more than one arthropod.
In summary, the disclosed apparatus enables the operator to manufacture gland content solutions with tuneable material properties such as for example protein concentration or biochemical composition by controlling parameters such as buffer composition, dimensions of openings in a porous support, flow distance of materials inside the apparatus and size of the collection area.
Description of the Drawings
Fig. 1 shows the apparatus with a porous support according to the current invention. Fig. 2 shows the use of the apparatus for harvesting arthropod gland contents. Fig. 3 shows the method of use of the apparatus. Fig. 4 shows the stress strain curve of Example 4.
Fig. 5 shows the apparatus with a solid support according to the current invention.
Detailed Description of the Invention
Figs. 1 and 5 show an apparatus 5 used in the invention. The apparatus 5 comprises a container 10, a material collection area 20, and a buffer solution 30 with one or more additives 40. The one or more additives 40 may be added at any stage during the use of the apparatus or alternatively no additives 40 need to be added. The apparatus 5 further contains a height adjustable (indicated by the arrow) gland holding device 50 which holds one or more arthropod glands removed from arthropods in position to facilitate release (elution) of contents of the one or more glands. Optionally, the apparatus 5 contains a height and position adjustable (indicated by the arrows) support 60 with a pore size of 0.1 - 10 mm. The support 60 can be a porous net or a porous plate as indicated in Fig.1 or a solid plate as indicated by Fig.5. The buffer solution 30 may contain for example 100 mM Tris or any other buffer type known to one skilled in the art of protein purification. The additives 40 may be by way of example only a therapeutically active substances or colouring agents.
The method of use of the apparatus 5 for extracting arthropod gland content is shown in overview in Fig. 2 and is described in Fig. 3.
Fig. 2 shows the placement of the arthropod glands 70 on the holding device 50 (indicated by the arrow). To facilitate industrial harvesting of the silkworm glands, the holding device 50 is automatically loaded with the arthropod glands 70 by one or several robotic gland pick-up and transfer devices 80. However, for small scale production, the apparatus 5 can also be loaded manually. The gland content 90 is released out of the arthropod gland 70 and is collected in the material collection area 20. Optionally, the porous support 60 may be used to improve homogeneous mixing with and increase exposure of the gland content 90 to the buffer 30 with or without the additives 40. By changing the positions of holding device 50 and porous support 60 relative to each other and relative to the material collection area 20, the apparatus 5 enables adjustment of the required concentration of the collected gland content 90.
Alternatively, no porous support 60 may be used at all thereby preserving the concentration of eluted gland content 90 as much as possible.
Fig. 3 summarises the method of use for apparatus 10.
In a first step 200 the container 10 is filled with the buffer 30 with or without the one or more additives 40.
In a next step 210, the glands 70 are extracted from bodies of the arthropods, such as silkworms. This can be done, for example, using a method described in US Patent No. 7,041,797. At least one opening is made into an epithelial cell wall of the silkworm glands so that the content (silk proteins) can be released from the inside of the silkworm glands. The opening in the epithelial cell wall can be made by ultrasound, mechanical cutting or enzymatic dissection. The opening in the epithelial cell wall can also be carried out by cutting the silkworm gland roughly in half. The exact position of the opening in the epithelial cell wall and method of making the opening are not crucial for practicing the invention. The opened glands 70 are then placed either manually or with one of the robotic pick-up and transfer devices 80 onto the holding device 50 of the apparatus 10. Such pick-and-place devices are known to one skilled in the art of laboratory automation and allow the physical manipulation of the silkworm gland 70 by means of a pick-and-place functional device, such as a gripper. The transferred silkworm glands 70 are arranged on the holding device 50 in a manner enabling the efficient release of the content 90 of the silkworm gland 70 and an efficient packing of the silkworm glands 70 inside the container 10. In one embodiment of the invention, the silkworm glands 70 from about 7 silkworms are used, however this is not limiting of the invention and can be easily scaled up to several magnitudes by increasing the dimensions of the holding device 50 and of the apparatus 5.
In the next step 220, gland content 90 flows out of the silkworm gland 70 into the container 10 and is collected in the material collection area 20. Optionally, the gland content 90 passes through porous support 60. As discussed above, the use of the porous support 60 has the advantage of improving homogeneity and adjusting material properties of the gland content 90 by varying the positions of the porous support 60 and/or the holding device 50 in the container 10. In addition, the porous support 60 may also be used for reducing impurities from the released gland content 90.
In step 230, the gland content 90 collected in the material collection area 20 may be stored in the container 10 or transferred into a further suitable storage containers (not shown). The collected gland content 90 has a protein content of around 1-30% and can be loaded with useful additives during or after the extraction process to confer novel functionality to the
collected gland material. In addition, the collected gland content 90 is substantially homogeneous, especially if the collected gland content 90 was passed through the porous support 60. This homogeneous distribution of the collected gland content 90 and the ability to confer the one or more additives to the gland contents 90 contrasts with prior art methods in which it has not been possible to mix the material native silk proteins from more than one silkworm gland 70 or to incorporate the one or more additives 40 into the material..
It should be noted that this method is equally applicable to native proteins and peptides (not only limited to silk proteins) and their recombinant analogous and fusion proteins extracted in native form from the glands of wild type or recombinant arthropods such as silkworms from the family Bombycidae, including but not limited to silkworms from the genera Antherea, Attacus, Samia, Bombyx and Telea. The extracted materials include, but are not limited to, ABAB-block polymer type peptides and proteins, such as fibroin.
The one or more additives 40 can be added to the extracted gland content 90, either to the buffer solution 30 at any stage of the extraction or directly to gland content 90 harvested in the material collection area 20.
The range of additives that can be added is extensive and it is envisaged that the following additives could be used:
• Organic additives: o Small molecular entities o ' Peptides o Proteins o Carbohydrates o Lipids o Nucleic acids such as DNA, RNA, PNAs and other nucleic acid analogues with more than 100 bases length as well as fragments thereof with less than 100 bases length such as for example siRNAs
• Inorganic additives: o Additives or precursors that improve or render mechanical, optical, electrical or catalytic properties
o Minerals such as phosphates, carbonates, sulphates, fluorides, silicates etc. and mineraloids such as clays, talc, and silicas, o Salts of alkali and alkaline earth metals, transition metals, post transition metals and alloys thereof, o Metal complexes such as metal ions coordinated with EDTA or other chelating agents, o Insulators such as metal oxides like Fe2O3, Al2O3, TiO2, o Any IH-V or II- VI semiconductor and conductors, such as metals and alloys thereof, o Carbon-based additives, such as fullerenes, carbon nanotubes, fibres or rods, graphite
• Hydrophobic, hydrophilic or amphiphilic additives to adjust the solubility of the gland content in the buffer solution and thus provide differing concentrations of extracted material.
• Nanoparticles
• Physiologically active compounds such as o Antibodies and their analogous o Antiseptics, antiviral agents and antibiotics o Anti-coagulants and anti-thrombotics o Vasodilatory agents o Chemotherapeutic agents o Antiproliferative agents o Anti-rejection or immunosuppressive agents o Agents acting on the central and peripheral nervous system o Analgesics o Anti-inflammatory agents o Hormones such as steroids o Mineralization agents for tooth regeneration such as fluorapatite for tooth regeneration o Mineralization agents for bone regeneration such as hydroxylapatite, tricalcium phosphate, marine animal derived particles such as corals and chitosans and the like o Growth factors such as • bone morphogenic proteins BMPs
• bone morphogenic-like proteins GFD 's
• epidermal growth factors EGFs
• fibroblast growth factors FGFs
• transforming growth factors TGFs • vascular endothelial growth factors VEGFs
• insulin-like growth factors IGFs
• nerve repair and regeneration factors NGFs
• platelet-derived growth factors PDGFs o Proteins functioning as cell or protein binding agents such as collagen IV, polylysine, fibronectin, cadherins, ICAM, V-CAM, N-CAM, selectins, neurofascins, oxonin, neuroglinin, fascilin o Cell-binding motives such as for example the RGD or RADAR recognition sites for cell adhesion molecules o Wound healing agents o Agents for preventing scar-formation such as for example Cordaneurin o Other naturally derived or genetically engineered therapeutically active proteins, polysaccharides, glycoproteins or lipoproteins o Therapeutically active cells such as for example stem cells or autologous cells derived from a site of the patient • Agents for detecting changes of pH such as neutral red
• Agents promoting β-sheet formation of the extracted gland proteins
• Agents such as biodegradable polymers which degrade at controllable rates thereby enabling controlled biodegradability
• Agents such as protease inhibitors which inhibit protease activity for example in the site of implantation in the patient thereby enabling controlled biodegradability
• Aprotic solvents improving hydrogen bond formation in silk proteins such as ether, ester, acidanhydride, ketones (e.g. acetone), tertiary amines, dimethylformamide, pyridine, furane, thiophen, trichlorethane, chloroform and other halogenated hydrocarbons, dimethylsulphoxide, dimethylsulphate, dimethylcarbonate, imsol, anisol, nitromethane.
• Agents enhancing release of physiologically active compounds
• Naturally derived or chemically synthesised dyes
• Naturally derived or genetically engineered colouring agents such as green fluorescent protein
• Naturally derived or genetically engineered structural load bearing proteins such as actin, silk, collagen or fibronectin and analogous or derivates thereof
• Electrically conducting and semi-conducting materials
• Polyelectrolytes with bound positive or negative charges • Ionic liquids
• Materials conferring transient or permanent magnetism
• Water soluble polymers such as polylactic acid or polycaprolactone
• Glass fibres
It should be understood that the list of additives is not intended to be limiting of the invention but is exemplary of the additives that can be added to the extracted gland material 90.
The extracted gland material 90 can be used for forming objects, for example by coating, moulding or spinning as defined in the spinning apparatus disclosed in European Patent 1244828. If the one or more additives 40 are added to the extracted gland material 90, the formed objects can have additional properties. For example, one of the additives 40 to encourage the growth of tissue could be added to the extracted gland material 90 so that the formed objects can be used as a medical implant.
Examples
Example 1
The silkworm glands of four Bombyx mori silkworms at the end of their fifth instar were extracted by removing the silkworm gland from the body of the Bombyx mori silkworms as described above with reference to the US Patent No. 7,041,797. Each of the silkworm glands was cut into half. The posterior halves of the silkworm glands were placed with a pair of forceps on a net positioned inside a Petri dish which was filled with 100 mM ammonium acetate buffer having a pH 7.8. In total, eight posterior silkworm glands 70 were transferred. The eight silkworm glands 70 were incubated for 60 min for osmotic shock and release of the content of the silkworm gland 70. The emptied silkworm glands 70 were then removed from the surface of the net using a pair of forceps. Where necessary, a sliding movement over the edge of the Petri dish was used in order to extract any remaining silkworm gland material left inside the silkworm gland. The extracted silkworm gland material was left overnight on the
surface of the net which allowed the silkworm gland material to pass through the net and sediment at the bottom of the Petri dish. The net was then removed from the Petri dish and the silkworm protein from the silkworm gland harvested using a 5 ml disposable syringe.
Example 2
Eight posterior halves of the silkworm glands 70 were extracted as described in Example 1. Microscopic analysis of any remaining material stuck to the net and of the filtered gland content collected in the Petri dish demonstrated the efficient separation of epithelial cell debris and decomposed, denatured gland materials from the homogeneous gland content in the Petri dish.
Example 3
To demonstrate the possibility of incorporating additives 40 ("dopants") in the gland content during the extraction, eight posterior halves of the silkworm glands were extracted in a buffer solution of 100 mM ammonium acetate buffer and 1.75 mM neutral red. The buffer solution had a pH 7.8. This was compared with four posterior halves extracted in 100 mM ammonium acetate buffer solution at pH 7.8 without further additives. The addition of the additive 40 to the buffer solution did not lead to aggregation or destabilisation of the extracted gland material from the silkworm gland.
The gland material containing the neutral red additive was transferred into a Petri dish and dried at 50°C to form a film. The film was found to be stable and retained red colour when incubated in water at room temperature for three months, thus demonstrating the stable integration of the additive into the gland material.
The silkworm gland material was extracted as described above containing 0,18 mM neutral red additive was further tested successfully for spinnability using the biomimetic spinning device of European Patent 1244828 yielding uniformly red coloured silk fibres with diameter of about 5 μm collected on two aluminium reels.
Example 4, Material properties of extracted gland materials
A film was cast using the gland material extracted in accordance with the method of Example 1. The cast film was water insoluble and did not change its properties upon repeated wetting and drying in water or organic solvents. Tensile testing was performed in dH2O on a ZwickRoell TC-FR2.5TN tensile tester at lOmm/min with sample geometries of 40mm x 2,5mm x 0,06mm. The film exhibited breaking strength in dH2O of about 20 MPa at approximately 100% breaking elongation (for data see figure 4).
Example 5, Reproducibility of gland content extraction
The silkworm glands of seven Bombyx mori silkworms at the end of their fifth instar were extracted by removing the silkworm gland from the body of the silkworms as described for example in the US patent application number 7,041,797. Each of the silkworm glands was cut into half. The posterior halves of the silkworm glands (in total 14) were placed with a pair of forceps on a bar positioned at the top of a cylinder with approx. 30 mm diameter and approx. 100 mm length containing a 10OmM ammonium acetate, pH 7.8 buffer and a net with mesh size 1 mm, positioned at approx. 46 mm distance from the closed bottom of the cylinder. The whole content of the opened silk glands was released, passed through the net and collected at the bottom of the device. The protein concentration of the collected whole gland content was then determined by drying in an oven at 600C. The extraction procedure was performed five times, yielding gland protein concentrations of 7.0%, 7.2%, 7.2%, 6.7% and 7.1% and an overall protein concentration of 7 ± 0.22%
Example 6, Adjusting protein concentration of extracted gland content
Four silk gland extractions with 14 posterior halves each were performed with the apparatus.
For each one of the silk gland extractions, 14 posterior halves were prepared as described in Example 5. The concentration of the extracted gland content was adjusted by varying the position of the porous net to the bottom of the cylinder between 10 mm, 20 mm and 46 mm. One of the extractions was performed with the porous net removed allowing direct passage of the gland content from the gland to the bottom of the cylinder. The protein concentration of the collected whole gland content was then determined by drying in an oven at 60°C. The resulting protein concentrations were: 20% for extraction without the porous net, 15% with the net positioned at 10 mm distance from the bottom of the cylinder, 11% with 20 mm distance, 7% with 46 mm distance and 5% with 100 mm distance.
Claims
1. Apparatus for the extraction of material from a gland (70) of a wild type or recombinant arthropod comprising:
- a holding device (50) on which at least part of the gland (70) is held;
- a buffer solution (30) at least partially immersing the gland (70); wherein in use the material is released from the gland (70) into the buffer solution
(30).
2. The apparatus of claim 1, further incorporating a support (60).
3. The apparatus of any one of the above claims, further including a material collection area (20) in which the material is collected.
4. The apparatus of any one of the above claims, wherein the material is sedimented inside the apparatus.
5. The apparatus of any one of the above claims, further incorporating a pick-and- place device (80).
6. The apparatus of any one of the above claims, wherein the buffer solution has one or more additives (40).
7. The apparatus of any one of claims 2 to 6, wherein the support (80) is movable within the apparatus.
8. The apparatus of any one of claims 2 to 7, wherein the support (80) is non-porous.
9. The apparatus of any one of the above claims, wherein the holding device (50) is movable within the apparatus.
10. A method for the extraction of material from a gland (70) of a wild type or recombinant arthropod comprising:
- providing the gland (70) containing at least partially the material;
- making an opening in the gland (70);
- placing the gland (70) on a holding device (50), the gland (70) being at least partially immersed in a buffer solution (30) such that the material is released from the gland (70).
11. The method of claim 10, wherein the material is selected from the group consisting of proteins, peptides and combinations thereof.
12. The method of claim 10 or 11 , wherein the material is fibroin.
13. The method of any one of claims 10 to 12, wherein the arthropod can be any native or recombinant species from the family Bombycidae.
14. The method of one of claims 10 to 13, further comprising adding at least one additive (40) to the buffer solution.
15. The method of claim 14, wherein at least one additive (40) is a biologically active molecule.
16. The method of any one of claims 10 to 15, further comprising an adjustment of a distance between the holding device (50) and/or a support (60) and a material collection area (20).
17. The method of any one of claims 10 to 16, further comprising passing the released material through the support (60).
18. The method of any one of the claims 10 to 15, further comprising an adjustment of a distance between the support (60) and a material collection area (20).
19. The method of any one of claims 10 to 18, wherein providing the gland (70) comprises the removal of the gland (70) from a body of the arthropod.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07703571A EP1989223B1 (en) | 2006-03-01 | 2007-03-01 | Method and apparatus for extraction of arthropod gland |
CA2642793A CA2642793C (en) | 2006-03-01 | 2007-03-01 | Method and apparatus for extraction of protein material from silkworm glands |
AT07703571T ATE458001T1 (en) | 2006-03-01 | 2007-03-01 | METHOD AND DEVICE FOR EXTRACTING AN ARTHROPOD GLAND |
DK07703571.5T DK1989223T3 (en) | 2006-03-01 | 2007-03-01 | Method and apparatus for extracting glands from arthropods |
JP2008556718A JP5269616B2 (en) | 2006-03-01 | 2007-03-01 | Arthropod gland extraction method and apparatus |
DE602007004830T DE602007004830D1 (en) | 2006-03-01 | 2007-03-01 | METHOD AND DEVICE FOR EXTRACTION OF AN ARTHROPOD SPRAY |
PL07703571T PL1989223T3 (en) | 2006-03-01 | 2007-03-01 | Method and apparatus for extraction of arthropod gland |
US12/128,425 US8287913B2 (en) | 2006-03-01 | 2008-05-28 | Method and apparatus for extraction of protein material from arthropod glands and a membrane formed therefrom |
US12/486,977 US8105633B2 (en) | 2006-03-01 | 2009-06-18 | Method and apparatus for extraction of arthropod gland |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77778806P | 2006-03-01 | 2006-03-01 | |
US60/777,788 | 2006-03-01 | ||
GB0604089.3 | 2006-03-01 | ||
GB0604089A GB2435646A (en) | 2006-03-01 | 2006-03-01 | Apparatus and method of extraction of an arthropod gland |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/128,425 Continuation-In-Part US8287913B2 (en) | 2006-03-01 | 2008-05-28 | Method and apparatus for extraction of protein material from arthropod glands and a membrane formed therefrom |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007098951A2 true WO2007098951A2 (en) | 2007-09-07 |
WO2007098951A3 WO2007098951A3 (en) | 2007-10-18 |
Family
ID=36218912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/001775 WO2007098951A2 (en) | 2006-03-01 | 2007-03-01 | Method and apparatus for extraction of protein material from silkworm glands |
Country Status (12)
Country | Link |
---|---|
US (1) | US8287913B2 (en) |
EP (1) | EP1989223B1 (en) |
JP (1) | JP5269616B2 (en) |
AT (1) | ATE458001T1 (en) |
CA (1) | CA2642793C (en) |
DE (1) | DE602007004830D1 (en) |
DK (1) | DK1989223T3 (en) |
ES (1) | ES2339497T3 (en) |
GB (1) | GB2435646A (en) |
PL (1) | PL1989223T3 (en) |
PT (1) | PT1989223E (en) |
WO (1) | WO2007098951A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2177650A1 (en) | 2008-10-17 | 2010-04-21 | Spintec Engineering GmbH | Apparatus and method for the manfacture of a silk mono-filament with a high tensile strength |
EP2253336A1 (en) | 2009-05-15 | 2010-11-24 | Spintec Engineering GmbH | A silk medical device with antimicrobial properties and a method of manufacture thereof |
WO2013155404A1 (en) | 2012-04-13 | 2013-10-17 | Trustees Of Tufts College | Methods and compositions for preparing a silk microsphere |
WO2014145002A2 (en) | 2013-03-15 | 2014-09-18 | Kluge Jonathan A | Low molecular weight silk compositions and stabilizing silk compositions |
WO2016116767A1 (en) * | 2015-01-23 | 2016-07-28 | Friedrich Wilhelm Ludwig Paul Vollrath | New extraction technique of silk proteins |
US10034945B2 (en) | 2012-07-13 | 2018-07-31 | Trustees Of Tufts College | Silk powder compaction for production of constructs with high mechanical strength and stiffness |
US10285702B2 (en) | 2013-04-24 | 2019-05-14 | Trustees Of Tufts College | Bioresorbable biopolymer anastomosis devices |
US10335519B2 (en) | 2011-04-20 | 2019-07-02 | Trustees Of Tufts College | Dynamic silk coatings for implantable devices |
US10493179B2 (en) | 2008-10-09 | 2019-12-03 | Trustees Of Tufts College | Modified silk films containing glycerol |
US10653786B2 (en) | 2012-04-25 | 2020-05-19 | Trustees Of Tufts College | Silk microspheres and methods for surface lubrication |
US11376329B2 (en) | 2013-03-15 | 2022-07-05 | Trustees Of Tufts College | Low molecular weight silk compositions and stabilizing silk compositions |
US11643444B2 (en) | 2016-05-04 | 2023-05-09 | Trustees Of Tufts College | Silk nanofibrils and uses thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8105633B2 (en) * | 2006-03-01 | 2012-01-31 | Spintec Engineering Gmbh | Method and apparatus for extraction of arthropod gland |
EP2719374A1 (en) | 2012-10-12 | 2014-04-16 | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen | Drug delivery device |
CN104894655B (en) * | 2015-06-30 | 2017-06-16 | 广西立盛茧丝绸有限公司 | A kind of cocoons-boiling method of fresh cocoon |
CN108774750A (en) * | 2018-05-31 | 2018-11-09 | 杭州金利丝业有限公司 | A kind of new type water silk floss machine |
WO2020028918A1 (en) * | 2018-08-03 | 2020-02-06 | Trustees Of Tufts College | Automated process for silk fibroin extraction |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003037925A2 (en) * | 2001-10-31 | 2003-05-08 | Fritz Vollrath | Precursor silk feedstock for forming filaments |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR733934A (en) | 1931-03-24 | 1932-10-13 | Glanzstoff Ag | Process for making artificial silk with high quality yield by wet spinning process |
JPS5167785A (en) | 1974-12-02 | 1976-06-11 | Mihama Kk | Fuyokakosono seizohoho |
JPH02268693A (en) * | 1989-04-10 | 1990-11-02 | Asahi Chem Ind Co Ltd | Production of silk fibroin by culturing rear silk glands |
JPH03209399A (en) * | 1990-01-11 | 1991-09-12 | Terumo Corp | Production of fibroin |
JPH0970241A (en) * | 1995-07-05 | 1997-03-18 | Toray Ind Inc | Dissection of silkworm |
JPH0919238A (en) * | 1995-07-05 | 1997-01-21 | Toray Ind Inc | Incision of silk worm |
GB9927950D0 (en) | 1999-11-27 | 2000-01-26 | Knight David P | Apparatus and method for forming materials |
JP2001163899A (en) | 1999-12-09 | 2001-06-19 | Natl Inst Of Sericultural & Entomological Science | Method for producing functional silk fibroin and its use |
JP2002128691A (en) | 2000-10-24 | 2002-05-09 | National Institute Of Agrobiological Sciences | Sericin-containing raw material, method for producing the same and method for using the same |
JP3973886B2 (en) * | 2001-11-29 | 2007-09-12 | 岡本レース株式会社 | Method for extracting sericin, extract thereof and method for modifying fiber or fabric |
JP2003180335A (en) * | 2001-12-21 | 2003-07-02 | Sumitomo Bakelite Co Ltd | Storable culture vessel |
CA2483524A1 (en) | 2002-07-16 | 2004-01-22 | National Institute Of Agrobiological Sciences | Electroporation method including the use of depressurization/pressurization |
GB0229993D0 (en) | 2002-12-23 | 2003-01-29 | Spinox Ltd | Method and apparatus for forming objects |
US20060257854A1 (en) | 2004-02-27 | 2006-11-16 | Mcdevitt John T | Membrane assay system including preloaded particles |
US20090042215A1 (en) | 2004-05-12 | 2009-02-12 | Colin John Ingham | Cell Permeability Assay in a Living Array of Multiple Cell Types and Multiple Layers of a Porous Substrate |
CA2608862C (en) | 2004-06-11 | 2020-05-05 | Trustees Of Tufts College | Silk-based drug delivery system |
WO2006052822A2 (en) | 2004-11-05 | 2006-05-18 | Cytolution, Inc. | Methods and devices for screening cervical cancer |
PA8851101A1 (en) | 2008-12-16 | 2010-07-27 | Lilly Co Eli | AMINO PIRAZOL COMPOUND |
US8968785B2 (en) | 2009-10-02 | 2015-03-03 | Covidien Lp | Surgical compositions |
-
2006
- 2006-03-01 GB GB0604089A patent/GB2435646A/en not_active Withdrawn
-
2007
- 2007-03-01 PL PL07703571T patent/PL1989223T3/en unknown
- 2007-03-01 DE DE602007004830T patent/DE602007004830D1/en active Active
- 2007-03-01 PT PT07703571T patent/PT1989223E/en unknown
- 2007-03-01 WO PCT/EP2007/001775 patent/WO2007098951A2/en active Application Filing
- 2007-03-01 JP JP2008556718A patent/JP5269616B2/en not_active Expired - Fee Related
- 2007-03-01 CA CA2642793A patent/CA2642793C/en not_active Expired - Fee Related
- 2007-03-01 AT AT07703571T patent/ATE458001T1/en active
- 2007-03-01 ES ES07703571T patent/ES2339497T3/en active Active
- 2007-03-01 EP EP07703571A patent/EP1989223B1/en not_active Not-in-force
- 2007-03-01 DK DK07703571.5T patent/DK1989223T3/en active
-
2008
- 2008-05-28 US US12/128,425 patent/US8287913B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003037925A2 (en) * | 2001-10-31 | 2003-05-08 | Fritz Vollrath | Precursor silk feedstock for forming filaments |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Week 200405 Derwent Publications Ltd., London, GB; AN 2004-046525 XP002443097 "Extraction of sericin for modifying textiles, involves immersing raw silk into strong electrolyzed water produced by electrolyze-dissolving crystalline clay mineral" & JP 2003 165843 A (BEST KOBO KK) 10 June 2003 (2003-06-10) * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10493179B2 (en) | 2008-10-09 | 2019-12-03 | Trustees Of Tufts College | Modified silk films containing glycerol |
US20100095827A1 (en) * | 2008-10-17 | 2010-04-22 | Spintec Engineering Gmbh | Apparatus and method for the manufacture of a silk mono-filament with a high tensile strength |
EP2177650A1 (en) | 2008-10-17 | 2010-04-21 | Spintec Engineering GmbH | Apparatus and method for the manfacture of a silk mono-filament with a high tensile strength |
EP2253336A1 (en) | 2009-05-15 | 2010-11-24 | Spintec Engineering GmbH | A silk medical device with antimicrobial properties and a method of manufacture thereof |
US11266339B2 (en) | 2011-04-20 | 2022-03-08 | Trustees Of Tufts College | Dynamic silk coatings for implantable devices |
US10335519B2 (en) | 2011-04-20 | 2019-07-02 | Trustees Of Tufts College | Dynamic silk coatings for implantable devices |
WO2013155404A1 (en) | 2012-04-13 | 2013-10-17 | Trustees Of Tufts College | Methods and compositions for preparing a silk microsphere |
US11576862B2 (en) | 2012-04-13 | 2023-02-14 | Trustees Of Tufts College | Methods and compositions for preparing a silk microsphere |
US10653786B2 (en) | 2012-04-25 | 2020-05-19 | Trustees Of Tufts College | Silk microspheres and methods for surface lubrication |
US10034945B2 (en) | 2012-07-13 | 2018-07-31 | Trustees Of Tufts College | Silk powder compaction for production of constructs with high mechanical strength and stiffness |
WO2014145002A2 (en) | 2013-03-15 | 2014-09-18 | Kluge Jonathan A | Low molecular weight silk compositions and stabilizing silk compositions |
EP3412682A1 (en) | 2013-03-15 | 2018-12-12 | Trustees Of Tufts College | Low molecular weight silk compositions and stabilizing silk compositions |
US11376329B2 (en) | 2013-03-15 | 2022-07-05 | Trustees Of Tufts College | Low molecular weight silk compositions and stabilizing silk compositions |
EP4180448A1 (en) | 2013-03-15 | 2023-05-17 | Trustees of Tufts College | Low molecular weight silk compositions and stabilizing silk compositions |
US10285702B2 (en) | 2013-04-24 | 2019-05-14 | Trustees Of Tufts College | Bioresorbable biopolymer anastomosis devices |
WO2016116767A1 (en) * | 2015-01-23 | 2016-07-28 | Friedrich Wilhelm Ludwig Paul Vollrath | New extraction technique of silk proteins |
US11643444B2 (en) | 2016-05-04 | 2023-05-09 | Trustees Of Tufts College | Silk nanofibrils and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US20080293918A1 (en) | 2008-11-27 |
JP2009528314A (en) | 2009-08-06 |
DE602007004830D1 (en) | 2010-04-01 |
GB2435646A (en) | 2007-09-05 |
CA2642793A1 (en) | 2007-09-07 |
PT1989223E (en) | 2010-04-14 |
EP1989223A2 (en) | 2008-11-12 |
DK1989223T3 (en) | 2010-06-07 |
WO2007098951A3 (en) | 2007-10-18 |
CA2642793C (en) | 2013-10-01 |
EP1989223B1 (en) | 2010-02-17 |
PL1989223T3 (en) | 2010-07-30 |
GB0604089D0 (en) | 2006-04-12 |
ES2339497T3 (en) | 2010-05-20 |
US8287913B2 (en) | 2012-10-16 |
ATE458001T1 (en) | 2010-03-15 |
JP5269616B2 (en) | 2013-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1989223B1 (en) | Method and apparatus for extraction of arthropod gland | |
US20190106467A1 (en) | Chimeric spider silk and methods of use thereof | |
DE68928532T2 (en) | FUNCTIONAL SYNTHETIC PROTEIN POLYMER PRODUCED BY A RECOMBINANT METHOD | |
ES2533555T3 (en) | Spider silk proteins and methods to produce spider silk proteins | |
CN101507843B (en) | Multi-purpose surgery biology patching material | |
RU2545331C2 (en) | Method of obtaining polymer-containing fibres | |
DE60115271T2 (en) | METHOD FOR PRODUCING SILK FIBROUS LIQUIDS | |
Hsia et al. | Spider silk composites and applications | |
Konwarh et al. | Opportunities and challenges in exploring Indian nonmulberry silk for biomedical applications | |
Debabov et al. | Recombinant spidroins as the basis for new materials | |
CN107556377B (en) | Recombinant human collagen and medical nanofiber membrane thereof | |
EP3573672B1 (en) | Templated assembly of collagen fibers and uses thereof | |
CN113416264B (en) | Triblock polypeptide and collagen bionic material formed by self-assembly of triblock polypeptide | |
RU2483756C1 (en) | METHOD FOR PREPARING BIODEGRADED COMPOSITE MATRIX OF REGENERATED SILK FIBROIN Bombyx mori AND ITS USE | |
CN111094326A (en) | Method for producing a concentrated binding phase of a silk fusion protein | |
US8105633B2 (en) | Method and apparatus for extraction of arthropod gland | |
Lang et al. | Properties of engineered and fabricated silks | |
CN104119451A (en) | Cationization silk fibroin and preparation method thereof | |
EP3966314A1 (en) | Alginate dialdehyde-collagen hydrogels and their use in 3d cell culture | |
EP3440099A1 (en) | Polymer-based material having covalently bonded, enzymatically degradable peptide sequences | |
CN108543112A (en) | Preparation method and products thereof with the silk gum-agarose plural gel for promoting cell-proliferation activity | |
Wu et al. | A novel 3D printed type II silk fibroin/polycaprolactone mesh for the treatment of pelvic organ prolapse | |
Trossmann et al. | Spider silk and blend biomaterials: recent advances and future opportunities | |
Ashton | The adhesive silk of the aquatic caddisfly larva: Structure, mechanics, and fiber spinning | |
Arndt | Biomimetic Spider Silk and Bioactive Hydrogels Formed By Engineered Recombinant Spider Silk Proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007703571 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008556718 Country of ref document: JP Ref document number: 2642793 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |